09995.HKLicensing•prnewswire•
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
Sentiment:Neutral (60)
Summary
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 19, 2025 by prnewswire